This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Get just this article for as long as you need it
$39.95
Prices may be subject to local taxes which are calculated during checkout

Data availability
Individual participant data will not be shared. For original data, please contact huangxiaojun@bjmu.edu.cn.
References
Young NS. Aplastic Anemia. N Engl J Med. 2018;379:1643–56. https://doi.org/10.1056/NEJMra1413485. e-pub ahead of print 2018/10/26.
Georges GE, Doney K, Storb R. Severe aplastic anemia: allogeneic bone marrow transplantation as first-line treatment. Blood Adv. 2018;2:2020–8. https://doi.org/10.1182/bloodadvances.2018021162. e-pub ahead of print 2018/08/16.
Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, et al. Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. Blood Adv. 2019;3:3123–31. https://doi.org/10.1182/bloodadvances.2019000722. e-pub ahead of print 2019/10/28.
Kako S, Yamazaki H, Ohashi K, Ozawa Y, Ota S, Kanda Y, et al. Mixed Chimerism and Secondary Graft Failure in Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia. Biol Blood Marrow Transpl. 2020;26:445–50. https://doi.org/10.1016/j.bbmt.2019.10.004. e-pub ahead of print 2019/10/17.
Xu ZL, Cheng YF, Zhang YY, Mo XD, Han TT, Wang FR, et al. The incidence, clinical outcome, and protective factors of mixed chimerism following hematopoietic stem cell transplantation for severe aplastic anemia. Clin Transpl. 2021;35:e14160 https://doi.org/10.1111/ctr.14160. e-pub ahead of print 2020/11/23.
Dulley FL, Vigorito AC, Aranha FJ, Sturaro D, Ruiz MA, Saboya R, et al. Addition of low-dose busulfan to cyclophosphamide in aplastic anemia patients prior to allogeneic bone marrow transplantation to reduce rejection. Bone Marrow Transpl. 2004;33:9–13. https://doi.org/10.1038/sj.bmt.1704325. e-pub ahead of print 2003/10/28.
Apsel Winger B, Shukla P, Kharbanda S, Keizer RJ, Goswami S, Cowan MJ, et al. The Relationship Between Busulfan Exposure and Achievement of Sustained Donor Myeloid Chimerism in Patients with Non-Malignant Disorders. Transpl Cell Ther. 2021;27:258 e251–258 e256. https://doi.org/10.1016/j.jtct.2020.12.005. e-pub ahead of print 2021/03/31.
Qin X, Zhu YP, Luo CJ, Zhou M, Huang K, Chen C, et al. Optimizing conditioning regimen with low-dose irradiation or busulfan enables the outcome of transplantation from a 6-7/8 HLA-matched donor comparable to that from an 8/8 HLA-matched unrelated donor in severe aplastic anemia patients under 40 years. Ann Hematol. 2021;100:2363–73. https://doi.org/10.1007/s00277-021-04540-w. e-pub ahead of print 2021/05/15.
Xu ZL, Xu LP, Zhang YY, Cheng YF, Mo XD, Wang FR, et al. Incidence and predictors of severe cardiotoxicity in patients with severe aplastic anaemia after haploidentical haematopoietic stem cell transplantation. Bone Marrow Transpl. 2019;54:1694–1700. https://doi.org/10.1038/s41409-019-0509-1. e-pub ahead of print 2019/03/25.
Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016;3:e526–e536. https://doi.org/10.1016/S2352-3026(16)30114-4. e-pub ahead of print 2016/10/18.
Xu L-P, Xu Z-L, Wang S-Q, Wu D-P, Gao S-J, Yang J-M, et al. Long-term follow-up of haploidentical transplantation in relapsed/refractory severe aplastic anemia: a multicenter prospective study. Sci Bullet. 2022; https://doi.org/10.1016/j.scib.2022.01.024.
Acknowledgements
This work was partly supported by National Natural Science Foundation of China (Grant No. 82100227), Foundation for Innovative Research Groups of the National Natural Science Foundation of China (Grant No. 81621001), and The National Key Research and Development Program of China (No. 2017YFA0104500).
Author information
Authors and Affiliations
Contributions
XJH designed the research; LPX, ZLX and XJ analysed the data and wrote the paper; and all authors, provided patient data and gave final approval for the paper.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Xu, LP., Xu, ZL., Zhang, YY. et al. Bulsufan decreases the incidence of mixed chimaerism in HLA-matched donor transplantation for severe aplastic anaemia. Bone Marrow Transplant 57, 1204–1206 (2022). https://doi.org/10.1038/s41409-022-01682-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-022-01682-x